Anti-diabetic compounds and their patent information: An update

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 1, 2013, Pages 35-48

  Pandey, Rajesh ^a   Kumar, Narendra ^b   Yadav, Mukesh ^c   Nagpal, Ravinder ^d   Jain, Shalini ^e   Yadav, Hariom ^e  

^a A P S UNIVERSITY   (India)

^b IMS ENGINEERING COLLEGE   (India)

^c College of Advance Studies ^*  (India)

^d Shaheed Udham Singh College of Research and Technology   (India)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Compound; Diabetes mellitus; Drug; Hyperglycemia; Insulin analogs receptor; Mechanisms; Organs; Patents; Regulation controlling drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BUFORMIN; CARBUTAMIDE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MEGLITINIDE; METAHEXAMIDE; NATEGLINIDE; PARANDIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; RIVOGLITAZONE; ROSIGLITAZONE; SALICYLIC ACID; SULFONAMIDE; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; APLASTIC ANEMIA; BACKACHE; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG MECHANISM; DYSLIPIDEMIA; DYSPEPSIA; EPIGASTRIC FULLNESS; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; HEADACHE; HEART INFARCTION; HEARTBURN; HOMEOPATHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; INSULIN RESISTANCE; INSULIN TREATMENT; JAUNDICE; LACTIC ACIDOSIS; LEUKOPENIA; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCREAS ISLET TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOCIAL STATUS; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 84874847214     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221313804004745     Document Type: Review

References (158)

1. Atkinson M, Maclaren N. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-36.
2. DeFronzo RA, Bonadonna RC, Ferannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992; 15:318-68.
3. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-7.
4. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-9.
5. Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: Management of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 2008; 15(2):142-6.
6. Xie W, Xing D, Zhao Y. A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit. Eur J Pharmacol 2005; 510(1-2): 113-20.
7. Xie W, Du L. High-cholesterol diets impair short-term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory nor retention of memory in prediabetic mice. Life Sci 2005; 77: 481-95.
8. Xie WD, Nie Y, Du LJ, Zhang YO, Cai GP. Preventive effects of fenofibrate and vitamin C on the development of type 2 diabetes and its complications in NIH mice induced by small-dose streptozotocin and lard. Pharmacol Res 2007; 55: 392-9.
9. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemics. Nature 2001; 414: 782-7.
10. Lebovitz HE. Insulin secretogogues: Old and new. Diabetes Rev 1999; 7: 139-53.
11. Haffner SM, Miettinin H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of type 2 DM in Mexican-Americans. Diabetes 1995; 44:1386-91.
12. Diabetes Atlas. International Diabetes Federation, Press Release, Cape Town, South Africa, 2006.
13. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults, the third National health and Nutrition examination survey, 1988-1994. Diabetes Care 1998; 21:518-24.
14. King H, Rewers M. Global estimates for prevalence of diabetes and impaired glucose tolerance in adults. Diabetes Care 1993; 16:157-77.
15. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middleincome countries. Lancet 2007; 8: 1929-38.
16. Nwobu CO, Johnson CC. Targeting obesity to reduce the risk for type 2 diabetes and other co-morbidities in African American youth: A review of the literature and recommendations for prevention. Diab Vasc Dis Res 2007; 4: 311-9.
17. Simmons D, Williams DR, Powell MY. Prevalence of diabetes in a predominately Asian community; findings of the Coventry diabetes study. Brit Med J 1989; 298:18-21.
18. Bril A, Ktorza A. A better understanding of the pathophysiology of obesity and type 2 diabetes: A clue for new therapeutic approaches. Curr Opin Pharmacol 2006; 6: 577-9.
19. Mshelia DS, Akinosun OM, Abbiyesuku FM. Effect of increased patient-physician contact time and health education in achieving diabetes mellitus management objectives in a resource-poor environment. Singapore Med J 2007; 48: 74-79.
20. Roger G. Epidemiology of diabetes. Adv Drug Deliv Rev 2002; 54: 1165-72.
21. Pomposelli R, Piasere V, Andreoni C, Costini G, Tonini E, Spalluzzi A, et al. Observational study of homeopathic and conventional therapies in patients with diabetic polyneuropathy. Homeopathy 2009; 98:17-25.
22. Jia W, Gaoz W, Tang L. Antidiabetic herbal drugs officially approved in China. Phytother Res 2003; 17:1127-34.
23. Liu JP, Zhang M, Wang WY, Grimsgaard S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database Syst Rev 2004; 3: CD003642.
24. Xie W, Xing D, Sun H, Wang W, Ding Y, Du L. The effects of Ananas comosus L. leaves on diabetic-dyslipidemic rats induced by alloxan and a high-fat/high-cholesterol diet. Am J Chin Med 2005; 33(1):95-105.
25. Xie W, Zhang Y, Wang N. Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice. Eur J Pharmacol 2008; 599:159-65.
26. Xie WD, Zhao YN, Du LJ, Cai GP, Gu DY, Zhang YO. Scorpion in combination with Gypsum: Novel antidiabetic activities in streptozotocin-induced diabetic mice by up-regulating pancreatic PPARβ and PDX-1 expressions. Evid Based Complement Alternat Med 2011; 2011: 683561.
27. Nicholson G, Hall GM. Diabetes mellitus: New drugs for new epidemics. Br J Anaesth 2011; 107(1):65-73.
28. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 antidiabetic treatment: Insulinotropic activity, glucose-stabilizing capability and proteolytic stability. Biochem Pharmacol 2007; 73:84-93.
29. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: What is the evidence? Diab Vasc Dis Res 2005; 2:61-6.
30. Lo D, Hilbush B, Mah S, Brayden D, Byrne D, Higgins L, et al. Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling. Adv Drug Deliv Rev 2002; 54:1213-23.
31. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119 (5 Suppl 1):10S-6S.
32. Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002; 54:1225-35.
33. Ulbrich K, Subr V, Podperova P, Buresova M. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release. J Control Release 1995; 34: 155-65.
34. Jiang HL, Zhu KJ. Pulsatile protein release from a laminated device comprising of polyanhydrides and pH-sensitive complexes. Int J Pharm 2000; 194:51-60.
35. Tildesley HD, Aydin CM, Ignaszewski A, Strelzow JA, Yu E, Bondy G. Sulfonylurea therapy is associated with increased NTproBNP levels in the treatment of type 2 diabetes. Int J Cardiol 2007; 115:312-7.
36. Neuvonen PJ, Karkkainen S, Lehtovaara R. Pharmacokinetics of chlorpropamide in epileptic patients: Effects of enzyme induction and urine pH on chlorpropamide elimination. Eur J Clin Pharmacol 1987; 32: 297-301.
37. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes. Diabetes 2004; 53:151-5.
38. nd ed., Wiley & Sons New York 1997.
39. Moses AM, Numann P, Miller M. Mechanism of chlorpropamideinduced antiduretics in man: Evidence for release of ADH and enhancement of periphera action. Metabolism 1973; 22:59-66.
40. Rendell M. The role of sulphonylureas in the management of T2DM. Drugs 2004; 64:1339-58.
41. Lindblad U, Lindwall K, Sjo strand A, Ranstam J, Melander A. The NEPI antidiabetes study (NANSY) 1 short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes Metab 2001; 3:443-51.
42. Bitzen PO, Melander A, Schersten B, Wahlin-Boll E. Influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycemia. Eur J Clin Pharmacol 1988; 35:31-7.
43. Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17:142-5.
44. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diab Res Clin Pract 2007; 77:58-61.
45. Hansen AM, Christensen IT, Hansen IB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the sulphonylurea receptor 1. Diabetes 2002; 51:2789-95.
46. Norman P, Rabasseda X. Nateglinide a structurally novel, shortacting, hypoglycemic agent. Drugs Today 2001; 37:411-26.
47. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-83.
48. nd ed. New York: Wiley & Sons 1997.
49. Sambol NC, Chiang J, Conner M, Liu CY, Lin ET, Goodman A. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012-21.
50. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract 2001; 121 (Suppl): 19-25.
51. Chapelsky MC, Thompson CK, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003; 43: 252-9.
52. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46:93-108.
53. McLeod JF. Clinical pharmacokinetics of nateglinide: A rapidly absorbed, short acting insulinotropic agent. Clin Pharmacokinet 2004; 43:97-120.
54. Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats and dogs. Arzneimittelforschung 1989; 39:1261-7.
55. +ATP channels, shows antileishanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother 2006; 12: 4214-6.
56. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001; 63: 1747-56.
57. Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am 1998; 82: 757-90.
58. Luna B, Hughes AT, Feinglos MN. The use of insulin secretagogues in the treatment of type 2 diabetes. Primary Care 1999; 26: 895-915.
59. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 9: 2526-30.
60. Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Renal function in type 2 diabetes with rosiglitazone, metformin and glyburide monotherapy. Clin J Am Soc Nephrol 2011; 5:1032-40.
61. st ed. New York: Cambridge University Press, 2010; 104.
62. Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, et al. Baseline characteristics of the Nateglinide and Valsartan Impaired glucose tolerance outcomes research trials population: Comparison with other diabetes prevention. Cardiovasc Ther 2010; (2):124-32.
63. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966; 7: 197-201.
64. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry A novel kinetic approach. J Biol Chem 1996; 271: 23222-9.
65. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, et al. Improved glucose tolerance via enhanced glucosedependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001; 284: 501-6.
66. McIntosh C, Demuth H, Pospisilik J, Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regul Pept 2004; 2: 159-65.
67. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 6: 626-30.
68. Al-Masri Ihab M, Mohammad K, Tahaa Mutasem O. Inhibition of dipeptidyl peptidase IV is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009; 24(5): 1061-6.
69. McIntosh CH. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci 2008; 13:1753-73.
70. McIntyre HF, Grant P. Dipeptidyl peptidase-IV inhibitors: Fixing type 2 diabetes? Br J Hosp Med (Lond) 2007; 68: 599-602.
71. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-80.
72. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Folet JE. LAF237 is a DPP-4 inhibitor that improves model-assessed beta-cell function in drug-naïve patients with type 2 diabetes. EASD conference: September 6-9, Munich, Germany, 2004.
73. Ghorpade, S.R., Gopalan, B., Joshi, H.V., Shah, D.M. Novel dipeptidyl peptidase IV inhibitors. WO05033099 (2005).
74. th ACS Meeting Philadelphia, USA 2004.
75. Magnin DR, Robl JA, Sulsky RB. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. J Med Chem 2004; 47:2587-98.
76. Augeri DJ, Robl JA, Betebenner DA. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48:5025-37.
77. 1st ACS Meeting Philadelphia, USA (2006).
78. Tadayyon M, Thomas L, Besenfelder U. Pharmacodynamic and pharmacokinetic characteristics of novel long-acting, xanthine based DPP-IV inhibitors in the rat and Rhesus monkey. Diabetes 2005; 546 (Suppl 1): Abs 565-P.
79. th ACS Meeting. Washington DC, USA 2005.
80. Parker JC, Hulin B, Vanvolkenburg MA, Lopaze MG, Sagawa K, Ogorman MT, et al. A novel fluorinated cyclic amide inhibitor of dipeptidyl peptidase IV improves glucose tolerance in murine models of diabetes mellitus. Diabetes 2003; 52 (Suppl 6): Abs 16-LB.
81. Chyan YJ, Chuang LM. Dipeptidyl peptidase-IV inhibitors: An evolving treatment for type 2 diabetes from the incretin concept. Recent Patents Endo Metabol Imm Drug Discov 2007; 1, 15-24.
82. Villhauer, E.B. N-(Substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US6110949 (2000).
83. Villhauer, E.B. N-substituted 2-cyanopyrrolidines. WO9819998 (1998), WO0034241 (2000), EP0937040 (2004) & SK0286635 (2009).
84. Ferlita, R.R., Hansen, K., Vydra, V.K., Wang, Y., Lindemann, C.M. Novel crystalline salts of a dipeptidyl peptidase-IV inhibitor. WO05072530 (2005) & EP1708571 (2009).
85. Chen, A.M., Wenslow, R.M. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor. WO05030127 (2005) & EP1667524 (2009).
86. Wenslow, R.M., Armstrong, J.D., Chen, A.M., Cypes, S., Ferlita, R.R., Hansen, K., Lindemann, C.M., Spartalis, E. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor. WO05020920 (2005).
87. Dreher, S.D., Ikemoto, N., Njolito, E., Rivera, N.R., Tellers, D.M., Xiao, Y. Process to chiral beta-amino acid derivatives. WO04085661 (2005).
88. Edmondson, S.D., Fisher, M.H., Kim, D., Maccoss, M., Parmee, E.R., Weber, A.E., Xu, J. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes. WO03004498 (2003).
89. Sharma, P.N., Gublo, E.J., Galvin, G.M., Boettger, S., Racha, S. Process for preparing a dipeptidyl peptidase IV inhibitor and intermediates employed therein. WO05094323 (2006).
90. Robl, J.A., Sulsky, R., Augeri, D.J., Magnin, D.R., Hamann, L.G., Betebenner, D. A. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use. WO0168603 (2002).
91. Politino, M., Cadin, M.M., Skonezny, P. M., Chen, J.G. Process for preparing dipeptidyl IV inhibitors and intermediates therefor. WO05106011 (2006).
92. Vu, T.C., Brzozowski, D.B., Fox, R., Godfrey, J.D., Hanson, R.L., Kolotuchin, S.V., Mazzullo, J.A., Patel, R.N., Wang, J., Wong, K., Yu, J., Zhu, J., Magnin, D.R., Augeri, D.J., Hamann, L.G. Methods and compounds producing dipeptidyl peptidase IV inhibitors and intermediates thereof. WO04052850 (2006).
93. Sharma, P.N. Process for producing a dipeptidyl peptidase IV inhibitor. WO05115982 (2005).
94. Patel, R.N., Hanson, R.L., Gill, I., Brzozowski, D.B., Skonezny, P.M., Politino, M., Chen, J. G., Moris-Varas, F., White, B.J. Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors. WO05108594 (2005).
95. Desai, D., Li, B.V. Coated tablet formulation and method. WO05117841 (2005) & US7951400 (2011).
96. Sharma, P.N., Galvin, G. M., Boettger, S. D., Racha, S., Zhu, J., Melton, J., Mudryk, B. Ammonolysis process for the preparation of intermediates for DPP IV inhibitors. WO06020664 (2006).
97. Feng, J., Gwaltney, S.L., Stafford, J.A., Zhang, Z. Dipeptidyl peptidase inhibitors. WO05095381 (2005).
98. Feng, J., Gwaltney, S.L., Lam, B., Zhang, Z. Dipeptidyl peptidase inhibitors. US7825242 (2010).
99. Feng, J., Gwaltney, S.L., Wallace, M.B., Stafford, J. A., Zhang, Z. Dipeptidyl peptidase inhibitors. US7872124 (2011) & US8093382 (2012).
100. Feng, J., Gwaltney II, S. L., Kaldor, S.W., Stafford, J. A., Wallace, M. B., Zhang, Z. Dipeptidyl peptidase inhibitors. US20050070706 (2005) & US20050070531 (2005).
101. Gopalan, B., Joshi, H.V., Shah, D.M., Ghorpade, S. R. Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof. WO05033099 (2005).
102. Demuth, H.-U., Schlenzig, D., Hoffmann, T., Manhart, S. Prodrugs of DP IV-inhibitors. US7084120 (2006).
103. Demuth, H.-U., Hoffmann, T., Schlenzig, D., Heiser, U. Effectors of dipeptidyl peptidase IV for topical use. US6949515 (2005) & US7335645 (2008).
104. Schoenafinger, K., Jaehne, G., Defossa, E., Billen, G., Buning, C., Tschank, G., Werner, U. Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase IV. WO06015691 (2006) & WO06015699 (2006).
105. Fonseca VA, Kulkarni KD. Management of type 2 diabetes: Oral agents, insulin and injectables. J Am Diet Assoc 2008; 108: S29-S33.
106. Sheehan MT. Current therapeutic opinion in type 2 diabetes mellitus: A practical approach. Clin Med Res 2003; 1: 189-200.
107. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (2): CD004654.
108. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-94.
109. Kado S, Murakami T, Aoki A, Nagase T, Katsura Y, Noritake M, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55.
110. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-702.
111. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, The Rosiglitazone Clinical Trials Study Group. Onceand twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15.
112. Bell DS, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: Review of the evidence in animals and humans. Endocr Pract 2001; 7: 135-38.
113. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
114. Forst T, Lübben G, Hohberg C, Kann P, Sachara C, Gottschall V, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005; 12: 543-50.
115. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. ADOPT Study Group. Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. N Eng J Med 2006; 355: 2427-43.
116. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-53.
117. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus. Part I. Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008; 117: 440-90.
118. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-8.
119. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
120. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-89.
121. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-25.
122. Buse JB, The ACCORD Study Group. Action to control cardiovascular risk in diabetes (ACCORD) trial. Design and methods. Am J Cardiol 2007; 99: S21-S33.
123. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
124. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32:193-203.
125. Woo V. Important differences; Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: S52-3.
126. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. ADOPT Study Group. Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. N Eng J Med 2006; 355: 2427-43.
127. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-53.
128. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus. Part I. Thiazolidinediones and their evolving cardiovascularimplications. Circulation 2008; 117: 440-9.
129. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
130. Rosenstock J, Inzucchi SE, Seufert J, Fleck RR, Wilson CA, Mekki Q. Initial combination therapy with alongliptin and pioglitazone in drug-native patients with type 2 diabetes. Diabetes Care 2010; 11:2406-8.
131. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin requiring diabetes mellitus: Rationale and review of clinical data. Drugs 2004; 64: 1419-32.
132. Schmitz O, Brock B, Rungby J. Amylin agonists: A novel approach in the treatment of diabetes. Diabetes 2004; 53: S233-8.
133. Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: Observations from a pilot study. Endocr Pract 2009; 7:689-95.
134. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity Res 2004; 12: 661-8.
135. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 2000; 278: G946-51.
136. +-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000; 49: 990-5.
137. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320:323-30.
138. Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2002; 29:423-7.
139. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl-cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide. Biol Pharm Bull 1997; 20:354-9.
140. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76:2655-68.
141. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51:1145-9.
142. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355-60.
143. +-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4β-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chem Pharm Bull 1998a; 46:1545-55.
144. +-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4β-dehydroxyphlorizin derivatives. Chem Pharm Bull 1998b; 46:22-33.
145. +-glucose cotransporter inhibitors as antidiabetics. 1. Synthesis and pharmacological properties of 4β-Dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull 1996; 44:1174-80.
146. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88:787.
147. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327:268-76.
148. Li JM, Che CT, Lau CBS, Leung PS, Cheng CHK. Desoxyrhaponticin (3, 5-dihydroxy-4β-methoxystilbene 3-O-beta-Dglucoside) inhibits glucose uptake in the intestine and kidney: In vitro and in vivo studies. J Pharmacol Exp Ther 2007; 320:38-46.
149. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
150. Cefalu WT. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents. Clin Pharmacol Ther 2007; 81: 636-49.
151. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer. Diabetologia 2009; 52: 1699-708.
152. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
153. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009; 52: 1732-44.
154. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-54.
155. Gupta S, Chattopadhyay T, Pal Singh M, Surolia A. Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus. Proc Natl Acad Sci USA 2010; 107(30):13246-51.
156. Wyne KL, Mora PF. Insulin therapy in type 2 diabetes. Endocr Res 2007; 32: 71-107.
157. Burcelin R. The gut-brain axis: A major glucoregulatory player. Diabetes Metab 2010; 36 (Suppl 3): S54-8.
158. Yadav H, Jain S, Marotta F. Probiotics mediated modulation of gutflora might be a biotherapeutical approach for obesity and type 2 diabetes. Metabolomics 1:107e. doi: 10.4172/2153-0769.1000107e.